PubMed Health⌕ Search

Biomedical subjects

M Seyfarth

Publications and source records attributed to M Seyfarth.

At least 91 records · Page 5Linked to original sources
PubMed1982

Local BCG-immunotherapy in bladder cancer patients. Immunological follow-up studies.

In a controlled clinical study 10 patients with bladder cancer were treated with an additional local BCG-therapy. For this investigations only patients with tumour stage T1-2 NO MO were elected. The local BCG-therapy was done as intralesional BCG-injections, the interval between each management was 4 weeks over a period of 4 months to 1 year. Under this treatment in all 10 patients tumor regression in different forms was seen. In 5 patients the tumor was not more found, neither in clinical nor in histological examinations. Side effects of the therapy were: influenza-like syndrome (6 patients), mild temperature (6 patients), increase of liver transaminases (5 patients), and granulomas in lung and liver (2 patients). In the immunological follow-up studies we have seen an increase of the lymphocyte activity against tumor-associated antigen from bladder cancer tissue in the electrophoretic mobility test in 6 patients. The results in skin testing, using 5 recall-antigens and DNFB, showed an increase of reactivity in only 4 patients. The total number of lymphocytes increased over a longer period. We didn't find typical humoral changes. The results of our 10 patients show that an intralesional BCG-therapy could be successful in 5 patients. The effect of BCG for immunostimulation was seen in vitro in 6 patients and in vivo in 4 patients.

Aged↗
PubMed1982

[Current immunologic findings in bladder cancer].

As a result of the growing significance of immunological findings in malignant growths, more attention is being paid to these questions in the diagnosis and treatment of carcinomas of the urinary bladder in humans. In this particular field the findings are not very numerous. In the field of immunodiagnosis demonstrable immunoreactions caused by cells seem to possess greater significance. Skin tests have only had prognostic significance to date. In the field of immunotherapy a non-specific BCG treatment was carried out on a small number of patients with various forms of application. These results do not give any certain information. The author refers to studies on chemically induced carcinomas of the urinary bladder in animals.

Animals↗
PubMed1982

[The immunologic behavior of carcinoma in situ of the bladder].

A report is given on 13 patients with c. i. s. of the bladder, which are examined in vivo and in vitro with respect to their immune reactivity. In skin tests with 5 recall antigens and the primary antigen DNFB there is no difference as compared with a control group of 29 patients. In an EM test 11 of the 13 patients with c. i. s. reacted with histospecific lymphocyte sensitisation, 10 out of 13 positive results were obtained with the antigen HEP. These findings support the current view of c. i. s. of the bladder as the first stage of a malign degeneration.

Adult↗
PubMed1980

Diagnostic value of urinary fibrin degradation products.

The concentrations of fibrin degradation products (FDP) in the urine were determined by the passive hemagglutination test in 115 patients with biopsy-proven chronic proliferating glomerulonephritis (GN), 93 patients with urinary tract infection (UTI) and 23 patients who received kidney transplants. The active GN values (12.3 micrograms/ml) are significantly higher than those for latent GN (0.3 micrograms/ml). Those for acute UTI (9.2 micrograms/ml) are significantly higher than for chronic UTI (1.3 micrograms/ml). In contrast to the reports published by others, the numerous 'false-positive' and 'false-negative' values make diagnosis of the activity questionable. Prognostic value can be expected in GN with the nephrotic syndrome (NS): patients with steroid-sensitive NS excrete FDP and patients with steroid-resistant NS excrete larger quantities of FDP. We have confirmed that a rise in the urinary FDP level in transplantation is indicative of rejection. However, since 10 of 27 rejections were FDP-negative, the absence of FDP in the urine does not preclude rejection.

False Negative Reactions↗
PubMed1980

[Value of DNFB skin testing in patients with bladder cancer (author's transl)].

Dinitrofluorobenzene (DNFB) was used to sensitize 156 patients (124 patients with bladder cancer, 32 controls) to test their ability to be immunized with a newly encountered antigen. All control persons had a normal reaction to DNFB. 16.1% of the tumor patients reacted anerg. The reactivity of the cancer patients depended on the tumor stage. Patients with stage T 1 tumors reacted more positive than those with stage T 3 tumors. Unfortunately, these results had only a value for a group of patients and cannot be extrapolated for application to a given patient. Our results suggested that the prognosis of a cancer patient could be depend of the skin reactivity result. DNFB skin testing is a good method for the estimation of immune status in bladder cancer.

Aged↗
PubMed1979

[Value of the electrophoresis mobility test in the differential diagnosis of obscure kidney findings].

The differential diagnosis of unclear carcinoma-suspicious renal findings often finishes with the test-exposition and nephrectomy. Also when all modern diagnostic possibilities are used not always a clear establishment of the diagnosis may be achieved. The cell electrophoresis mobility test after Field and Caspary may contribute to the differential-diagnostic clarification of the findings, when adequate antigens are used. For this purpose 10 own cases are discussed and these results are compared with suitable comparative groups. Summarizingly by the present study can be shown that the immunologic diagnostics of tumours in the field of unclear renal tumours may be a very good help in the diagnostics. When adequate antigens are used in the cell electrophoresis mobility test a coordination concerning the histospecificity can be achieved.

Adult↗
PubMed1979

[DNFB reaction in bladder cancer, an immunological study].

It is stated that the determination of the reactivity against the primary antigen dinitrofluorbenzol by means of the epicutaneous skin test before the beginning of a therapy may give an essential reference to the spreading of the tumour and to the prognosis. The course control in patients with carcinoma of the urinary bladder should therefore consist not only of clinical but also of immunological examinations.

Aged↗
PubMed1978

A contribution to immunological tumour diagnostics in urology.

Fifty-four patients with malignant and other diseases of the urinary bladder and the prostate were examined for lymphocyte sensitization by means of electrophoretic mobility test (EM test). In this antigens from brain tissue (EF) and from malignomas of kidney, urinary bladder and prostate were used. Positive HEP values were obtained in 40 patients out of 42 with malignant tumours and in 5 patients out of 12 with other kidney diseases. With the corresponding tumour-associated antigens (TAA) in the EM-test, the histological tumour diagnosis could be confirmed in every case. Positive findings after using EF as well as the corresponding TAA are with great probability an indication of a malignant disease.

Adenocarcinoma↗
PubMed1978

[Diagnostic value of determining urinary fibrin split products in glomerulonephritis, pyelonephritis and graft rejection].

On 112 patients with bioptically ascertained chronic proliferative glomerulonephritis, 94 with pyelonephritis and 23 patients with kidney transplantation altogether 1,050 times the fibrin fission products in the urine were estimated by the passive haemagglutination after Merskey. It was the aim of the investigation to test the diagnostic evidence described in literature concerning the floridity diagnostics in glomerulonephritis and the recognition of rejection in kidney transplantation as to its reproducibility. In comparison to the latent glomerulonephritis (0.3 microgram/ml) the florid glomerulonephritis (12.3 microgram/ml) as well as the acute pyelonephritis (9.2 microgram/ml) in comparison to the chronic pyelonephritis (1.3 microgram/ml) has significantly higher values. On account of the numerous "falsely positive" and "falsely negative" values in contrast to the data of other authors an activity diagnostics is not possible. Only in the glomerulonephritis with nephrotic syndrome a prognostic use is to be expected: Patients with steroid-sensitive nephrotic syndrome do not secrete any fibrin fission products in the urine and patients with steroid-resistant nephrotic syndrome secrete them in a large number. We could confirm that an increase of the fibrin fission products in the urine after kidney transplantation refers to an acute rejection crisis. Since 10 of 27 rejections were fibrin fission product-negative, in the lacking fibrin fission products in the urine a rejection is not be excluded, by which the diagnostic value is restricted.

Fibrin Fibrinogen Degradation Products↗
PubMed1978

Urinary fibrin degradation products--a three year comparative study.

Urinary fibrin degradation products (FDP) were determined by Merskey's passive haemagglutination test in 115 patients with biopsy proven chronic proliferative glomerulonephritis (GN), 94 with urinary tract infection (UTI), and 23 transplanted patients. The active GN values (12.3 microgram/ml) are significantly higher than those for latent GN (0.3 microgram/ml). Those for acute UTI (9.2 microgram/ml) are significantly higher than for chronic UTI (1.3 microgram/ml). In contrast to the reports published by others, the numerous 'false positive' and 'false negative' values make diagnosis of the activity unreliable. Some prognostic value can be expected in GN with the nephrotic syndrome (NS): patients with steroid-sensitive NS excrete no FDP and patients with steroid-resistant NS excrete larger quantities of FDP. We have confirmed that a rise in FDP level following kidney transplantation is indicative of an acute rejection crisis. However, since 10 of 27 rejections were FDP negative, the absence of FDP in the urine does not preclude rejection, so that the diagnostic value is restricted.

False Negative Reactions↗
PubMed1978

[Course of cellular immunity in urologic neoplasms].

Apart from a purely qualitative evidence concerning the presence of a specific sensibilisation it is possible to estimate also its strength or the blocking factors appearing in the serum of tumour carriers by means of the electrophoresis mobility test. By this it seems to be possible to make an evidence concerning the immunological reaction position of the tumour patient with the possibility to make conclusions as to the prognosis of the patient.

Antigens, Neoplasm↗
PubMed1978

[A contribution to the early diagnosis and differential diagnosis of bladder neoplasms by means of immunological methods].

According to the present examinations it is pretty probable that already in early histological forms of the carcinoma of the urinary bladder the EM-test is able to indicate immunologically malignity, i.e. that the papillary non-infiltrating carcinoma of the transitional cell as well as the carcinoma in situ of the urinary bladder (23) also immunologically behave like tumors of the bladder. In differential-diagnostic questions concerning the organ localisation of the primary tumor the EM-test seems to give valuable references. Histologically not unequivocally malignant tumors of the bladder with positive results in the EM-test should be submitted to an exacter examination and control.

Adult↗
PubMed1977

[Immunodiagnosis of urologic tumors].

In 42 patients with malignant and benign diseases of the kidney, the urinary bladder and the prostate the sensitization of the lymphocytes was investigated in the cell electrophoresis mobility test. In these cases human encephalitogenic protein and tumour-associated antigens from malignomas of kidney, urinary bladder and prostate were used as antigen. When using human encephalitogenic protein 3 "falsely positive" and 2 "falsely negative" results were got, whereas, when using the corresponding tumour-associated antigens in the cell electrophoresis mobility test in every case the histologically ascertained tumour diagnosis could be confirmed.

Adenocarcinoma↗